RATIONALE: Apolipoprotein (apoA)-I mimetic peptides are a promising type of anti-atherosclerosis therapy, but how the structural features of these peptides relate to the multiple antiatherogenic functions of HDL is poorly understood. OBJECTIVE: To establish structure/function relationships of apoA-I mimetic peptides with their antiatherogenic functions. METHODS AND RESULTS: Twenty-two bihelical apoA-I mimetic peptides were investigated in vitro for the capacity and specificity of cholesterol efflux, inhibition of inflammatory response of monocytes and endothelial cells, and inhibition of low-density lipoprotein (LDL) oxidation. It was found that mean hydrophobicity, charge, size of hydrophobic face, and angle of the link between the helices are the major factors determining the efficiency and specificity of cholesterol efflux. The peptide with optimal parameters was more effective and specific toward cholesterol efflux than human apoA-I. Charge and size of hydrophobic face were also the major factors affecting antiinflammatory properties, and the presence of cysteine and histidine residues was the main factor determining antioxidant properties. There was no significant correlation between capacities of the peptides to support individual functions; each function had its own optimal set of features. CONCLUSIONS: None of the peptides was equally effective in all the antiatherogenic functions tested, suggesting that different functions of HDL may have different mechanisms and different structural requirements. The results do suggest, however, that rationalizing the design of apoA-I mimetic peptides may improve their therapeutic value and may lead to a better understanding of mechanisms of various antiatherogenic functions of HDL.
RATIONALE: Apolipoprotein (apoA)-I mimetic peptides are a promising type of anti-atherosclerosis therapy, but how the structural features of these peptides relate to the multiple antiatherogenic functions of HDL is poorly understood. OBJECTIVE: To establish structure/function relationships of apoA-I mimetic peptides with their antiatherogenic functions. METHODS AND RESULTS: Twenty-two bihelical apoA-I mimetic peptides were investigated in vitro for the capacity and specificity of cholesterol efflux, inhibition of inflammatory response of monocytes and endothelial cells, and inhibition of low-density lipoprotein (LDL) oxidation. It was found that mean hydrophobicity, charge, size of hydrophobic face, and angle of the link between the helices are the major factors determining the efficiency and specificity of cholesterol efflux. The peptide with optimal parameters was more effective and specific toward cholesterol efflux than humanapoA-I. Charge and size of hydrophobic face were also the major factors affecting antiinflammatory properties, and the presence of cysteine and histidine residues was the main factor determining antioxidant properties. There was no significant correlation between capacities of the peptides to support individual functions; each function had its own optimal set of features. CONCLUSIONS: None of the peptides was equally effective in all the antiatherogenic functions tested, suggesting that different functions of HDL may have different mechanisms and different structural requirements. The results do suggest, however, that rationalizing the design of apoA-I mimetic peptides may improve their therapeutic value and may lead to a better understanding of mechanisms of various antiatherogenic functions of HDL.
Authors: G Datta; M Chaddha; S Hama; M Navab; A M Fogelman; D W Garber; V K Mishra; R M Epand; R F Epand; S Lund-Katz; M C Phillips; J P Segrest; G M Anantharamaiah Journal: J Lipid Res Date: 2001-07 Impact factor: 5.922
Authors: Mohamad Navab; G M Anantharamaiah; Susan Hama; David W Garber; Manjula Chaddha; Greg Hough; Roger Lallone; Alan M Fogelman Journal: Circulation Date: 2002-01-22 Impact factor: 29.690
Authors: Alan T Remaley; Fairwell Thomas; John A Stonik; Steve J Demosky; Samantha E Bark; Edward B Neufeld; Alexander V Bocharov; Tatyana G Vishnyakova; Amy P Patterson; Thomas L Eggerman; Silvia Santamarina-Fojo; H Bryan Brewer Journal: J Lipid Res Date: 2003-01-16 Impact factor: 5.922
Authors: D O Sviridov; I Z Ikpot; J Stonik; S K Drake; M Amar; D O Osei-Hwedieh; G Piszczek; S Turner; A T Remaley Journal: Biochem Biophys Res Commun Date: 2011-06-06 Impact factor: 3.575
Authors: Scott M Gordon; Mohsen Pourmousa; Maureen Sampson; Denis Sviridov; Rafique Islam; B Scott Perrin; Georgina Kemeh; Richard W Pastor; Alan T Remaley Journal: Biochim Biophys Acta Biomembr Date: 2016-11-01 Impact factor: 3.747
Authors: Mohamad Navab; Srinivasa T Reddy; G M Anantharamaiah; Satoshi Imaizumi; Greg Hough; Susan Hama; Alan M Fogelman Journal: J Lipid Res Date: 2011-03-28 Impact factor: 5.922
Authors: Hann Low; Nigora Mukhamedova; Huanhuan L Cui; Brian P McSharry; Selmir Avdic; Anh Hoang; Michael Ditiatkovski; Yingying Liu; Ying Fu; Peter J Meikle; Martin Blomberg; Konstantinos A Polyzos; William E Miller; Piotr Religa; Michael Bukrinsky; Cecilia Soderberg-Naucler; Barry Slobedman; Dmitri Sviridov Journal: Cell Rep Date: 2016-06-16 Impact factor: 9.423